Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNT1 | O60563 | 2/20 | 0.52 |
| ▸ | CDK9 | P50750 | 2/20 | 0.52 |
| ▸ | CDK2 | P24941 | 2/20 | 0.48 |
| ▸ | CDK4 | P11802 | 1/20 | 0.48 |
| ▸ | GSK3B | P49841 | 1/20 | 0.48 |
| ▸ | BTK | Q06187 | 2/20 | 0.48 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.46 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.46 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | JAK2 | O60674 | 10/20 | 0.46 |
| ▸ | JAK1 | P23458 | 9/20 | 0.46 |
| ▸ | TYK2 | P29597 | 9/20 | 0.46 |
| ▸ | JAK3 | P52333 | 3/20 | 0.46 |
| ▸ | STAT3 | P40763 | 1/20 | 0.46 |
| ▸ | ABL1 | P00519 | 1/20 | 0.45 |
| ▸ | BCR | P11274 | 1/20 | 0.45 |
| ▸ | PRKCA | P17252 | 1/20 | 0.45 |
| ▸ | CAMK2D | Q13557 | 3/20 | 0.45 |
| ▸ | KDR | P35968 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22097651 | 0.90 | BTK (0.49) | CCNT1CDK9BTKMAPK3MAPK1 | |
| SCHEMBL29901235 | 0.89 | CDK4 (0.49) | CCNT1CDK9CDK2CDK4GSK3B | |
| SCHEMBL23275907 | 0.89 | CDK4 (0.49) | CCNT1CDK9CDK2CDK4GSK3B | |
| SCHEMBL29941570 | 0.85 | JAK2 (0.53) | CDK9CDK2BTKJAK2JAK1 | |
| SCHEMBL22097650 | 0.85 | JAK2 (0.53) | CDK9CDK2BTKJAK2JAK1 | |
| SCHEMBL23275696 | 0.83 | CAMK2D (0.66) | CDK2CDK4GSK3BBTKJAK2 | |
| SCHEMBL24853208 | 0.79 | MAPK1 (0.50) | BTKMAPK3MAPK1JAK2JAK1 | |
| SCHEMBL23275876 | 0.79 | BTK (0.49) | BTKJAK2JAK1TYK2JAK3 | |
| SCHEMBL23281912 | 0.79 | ABL1 (0.49) | CCNT1CDK9BTKJAK2JAK1 | |
| SCHEMBL15547217 | 0.77 | JAK2 (0.53) | BTKJAK2JAK1TYK2JAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250115586-A1 | BENZAMIDES OF PYRAZOLYLAMINO- PYRIMIDINYL DERIVATIVES, AND COMPOSITIONS AND METHODS THEREOF | LYNK PHARMACEUTICALS CO LTD (CN) | 2025-04-10 | — | — | US | disclosed |
| US-12030870-B2 | Benzamides of pyrazolylamino-pyrimidinyl derivatives, and compositions and methods thereof | LYNK PHARMACEUTICALS CO. LTD. (CN) | 2024-07-09 | — | — | US | disclosed |
| US-12030870-B2 | Benzamides of pyrazolylamino-pyrimidinyl derivatives, and compositions and methods thereof | LYNK PHARMACEUTICALS CO. LTD. (CN) | 2024-07-09 | — | — | US | disclosed |
| US-20240025882-A1 | BENZAMIDES OF PYRAZOLYLAMINO- PYRIMIDINYL DERIVATIVES, AND COMPOSITIONS AND METHODS THEREOF | LYNK PHARMACEUTICALS CO. LTD. (CN) | 2024-01-25 | — | — | US | disclosed |
| US-20240025882-A1 | BENZAMIDES OF PYRAZOLYLAMINO- PYRIMIDINYL DERIVATIVES, AND COMPOSITIONS AND METHODS THEREOF | LYNK PHARMACEUTICALS CO. LTD. (CN) | 2024-01-25 | — | — | US | disclosed |
| US-20230002362-A1 | BENZAMIDES OF PYRAZOLYLAMINO- PYRIMIDINYL DERIVATIVES, AND COMPOSITIONS AND METHODS THEREOF | LYNK PHARMACEUTICALS CO. LTD. (CN) | 2023-01-05 | — | — | US | disclosed |
| WO-2020118683-A1 | BENZAMIDES OF PYRAZOLYL-AMINO-PYRIMIDINYL DERIVATIVES, AND COMPOSITIONS AND METHODS THEREOF | LYNK PHARMACEUTICALS CO. LTD. (CN) | 2020-06-18 | — | — | WO | disclosed |
| WO-2020119819-A1 | BENZAMIDES OF PYRAZOLYL-AMINO-PYRIMIDINYL DERIVATIVES, AND COMPOSITIONS AND METHODS THEREOF | LYNK PHARMACEUTICALS CO. LTD. (CN) | 2020-06-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250115586-A1 | BENZAMIDES OF PYRAZOLYLAMINO- PYRIMIDINYL DERIVATIVES, AND COMPOSITIONS AND METHODS THEREOF | JAK1, JAK3, JAK2 | CCNT1 2373/4885CDK9 81/4885CDK2 115/4885 |
| US-12030870-B2 | Benzamides of pyrazolylamino-pyrimidinyl derivatives, and compositions and methods thereof | JAK2, JAK1, JAK3 | CCNT1 1641/4885CDK9 46/4885CDK2 49/4885 |
| US-20230002362-A1 | BENZAMIDES OF PYRAZOLYLAMINO- PYRIMIDINYL DERIVATIVES, AND COMPOSITIONS AND METHODS THEREOF | JAK1, JAK3, JAK2 | CCNT1 2373/4885CDK9 81/4885CDK2 115/4885 |
| US-20240025882-A1 | BENZAMIDES OF PYRAZOLYLAMINO- PYRIMIDINYL DERIVATIVES, AND COMPOSITIONS AND METHODS THEREOF | JAK2, JAK1, JAK3 | CCNT1 1641/4885CDK9 46/4885CDK2 49/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.